Back to Search
KAREN LEITZEL, M.D.
M.D.
Family Medicine Physician
NPI: 1528090800IndividualAccepts Medicare
Specialties, Licenses & Credentials
CMS Specialties
PrimaryFAMILY PRACTICE
Education
UNIVERSITY OF CHICAGO, PRITZKER SCHOOL OF MEDICINE
Class of 1995
Research & Publications (15)
Elevated plasma endoglin (CD105) predicts decreased response and survival in a metastatic breast cancer trial of hormone therapy.
PMID 19115106·Breast Cancer Res Treat·2010
3-trial
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer.
PMID 18443351·J Clin Oncol·2008
4-observational
Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
PMID 17407159·Cancer·2007
3-trial
Serum epidermal growth factor receptor/HER-2 predicts poor survival in patients with metastatic breast cancer.
PMID 17048231·Cancer·2006
3-trial
Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
PMID 15952182·Cancer·2005
8-other
Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer.
PMID 15245613·Clin Breast Cancer·2004
6-review
Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis.
PMID 14998848·Ann Oncol·2004
3-trial
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
PMID 14500583·Clin Chem·2003
1-meta
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1201 S MAIN ST, ATTN: ER DEPT
CROWN POINT, IN 46307 - Phone
- (219) 757-3218
Quick Facts
- NPI
- 1528090800
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 31
- Publications
- 15
Are you this provider?
Claim Your Profile